London scientists have made a breakthrough fighting the scourge of multiple sclerosis, fine-tuning MRIs to detect the disease before it ravages its victims.
“This could be a real game-changer,” said Dr. Bruce Bebo, who this year will decide how to invest $50 million in research raised by the National MS Society in the United States.
Bebo marvelled Thursday from afar at the work of a London research team headed by Dr. Ravi Menon that’s aimed at what has been an elusive target — finding and treating MS before it causes physical and cognitive impairment.
The challenge is especially pressing in Canada, where MS rates are the highest in the world — nine times higher than the world average.
Neurologists have long used MRIs to diagnose MS by showing damage to the protective sheath that insulates the body’s central nervous system.
Now, London researchers have fine-tuned a high-powered MRI to actually measure the amount of damage to that protective sheath —called myelin — as well as the deposits of iron typically found with the disease.
The team from Western University perfected the scans first on rats in a study published this month in the journal Proceedings of the National Academy of Sciences.
“It’s a huge step (forward),” Menon told The Free Press.
They then tested it on people, and though that study won’t be published until January, preliminary data showed that damage might be pinpointed
long before patients are traditionally diagnosed, potentially before they had suffered any ill effects.
“It’s really the holy grail, being able to track myelin,” Bebo said.
Though it’s not practical or affordable to screen everyone for MS using an MRI, research is underway to identify those most at risk from the disease. Some day, that work might lead to simpler tests such as a blood test to find those more at-risk who could then be scanned before the onset of symptoms, Bebo said.
In the meantime, more precise MRIs may help people already being treated for the disease with conventional drugs that suppress their immune system — it’s the immune system that attacks the myelin.
That treatment is by trial and error: If patients continue to deteriorate, doctors switch medications. Menon’s MRIs might help doctors switch away from failing medications before the damage occurs, Bebo said.
New research is aimed at reversing the damage to myelin, a task that may deliver even greater benefit if MS is discovered early, he said.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Multiple Sclerosis Treatment: New Insightson November 2, 2019 at 6:35 am
In patients with relapsing remitting multiple sclerosis EMA's safety committee (PRAC) has recommended restrictions on the use of Lemtrada (alemtuzumab). The recommendations reflect PRAC's review of ...
- Potential genetic markers of multiple sclerosis severityon October 31, 2019 at 6:28 am
In a bid to determine factors linked to the most debilitating forms of multiple sclerosis (MS), Johns Hopkins Medicine researchers say they have identified three so-called "complement system" genes ...
- The Right Notes raises $110K for those living with multiple sclerosison October 30, 2019 at 9:00 pm
SOMERS POINT — The Right Notes, South Jersey’s fight against MS, an annual fundraising event presented by the Donovan Financial Group of UBS Financial Services and benefiting the National Multiple ...
- FDA approves multiple sclerosis drug from Biogen and Alkermeson October 30, 2019 at 4:48 am
Oct 30 (Reuters) - Biogen Inc and partner Alkermes Plc said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat multiple sclerosis. The drug, Vumerity, was ...
- Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosison October 30, 2019 at 4:35 am
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis PR Newswire CAMBRIDGE, Massachusetts and DUBLIN, Oct. 30, 2019 – VUMERITY, a New Oral Treatment ...
- Biogen Inc.: Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosison October 30, 2019 at 4:31 am
and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY^™ ...
- Montel Williams opens up about his first symptoms of multiple sclerosison October 28, 2019 at 10:11 am
Nearly 2.3 million people are estimated to be living with multiple sclerosis around the world, but when Montel Williams received his official diagnosis back in 1999, not much was known about the ...
- Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)on October 28, 2019 at 6:36 am
NESS ZIONA, Israel, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple ...
- Speaking Multiple Sclerosis: A Glossary of Common Termson October 24, 2019 at 2:57 pm
Whether you’ve been recently diagnosed with multiple sclerosis (MS) or have been living with the condition for a while, chances are you’ll sometimes hear terms from your healthcare team that are new ...
- WTOP’s Dave Johnson on multiple sclerosis diagnosis: Acceptance, fear, determinationon October 24, 2019 at 2:24 am
WTOP Sports Director Dave Johnson was recently diagnosed with primary progressive multiple sclerosis. (Courtesy Facebook/Dave Johnson/Matt Mathai) WTOP Sports Director Dave Johnson had more than a ...
via Bing News